May 10, 2018 — As part of a growth vision centered on improving patient care quality and safety, Samsung has incorporated the S-Vue 3.02 engine on its GC85A premium fully digital X-ray system.
The S-Vue 3.02 received U.S. Food and Drug Administration (FDA) clearance last November for use at 50 percent dose reduction for adult chest exams.
When it comes to dose management, precision is key, according to Samsung. The GC85A incorporates Samsung’s Image Post-processing Engine S-Vue 3.02 that provides spatially adaptive multi-scale processing and advanced de-noising technology, delivering quality images with only half the dose.
“I recently participated in Samsung’s Low Dose Study and personally evaluated 10 chest X-rays, finding that the overall image quality was excellent,” said Hetal Patel, M.D., chief of radiology, ARMC-Moses Cone Health, Greensboro Radiology P.A. “The reduced-dose X-ray was either of comparable quality or better quality, and I would advocate for all chest X-rays to be done using this methodology.”
In practice, patients who receive a chest X-ray from the GC85A are subjected to 8 microsieverts (μSv) of radiation. To place that in context, it is as low as the average dose exposed during a three-hour flight from Chicago to New York.
In March, Samsung received Low Dose clearance from the South Korea Ministry of Food & Drug Safety (MFDS) and CE marked for applying dose reduction technology in other X-ray models.
Philip Sullivan, president and CEO of NeuroLogica, a Samsung subsidiary, said the company plans to expand dose-reduction protocols from chest to other parts of the body, such as the abdomen, and include pediatrics in the near future.
For more information: www.samsunghealthcare.com
July 30, 2024 
